For research use only. Not for therapeutic Use.
Reltecimod（Cat No.:I008999）is an investigational therapeutic agent primarily being studied for its potential in treating acute bacterial skin and skin structure infections (ABSSSI) and other inflammatory conditions. It is a small molecule that modulates the immune response by targeting and inhibiting specific components of the innate immune system, particularly the activation of neutrophils. This action aims to reduce excessive inflammation and tissue damage associated with infection. Although still in clinical trials, reltecimod shows promise as a treatment for conditions driven by severe bacterial infections and inflammation, with a focus on improving patient outcomes and reducing complications.
| Catalog Number | I008999 |
| CAS Number | 1447799-33-8 |
| Synonyms | Reltecimod; AB-103; P-2TA; AB103; P2TA; NSC-37096; BENZCARBIMINE.;(S)-3-((S)-2-((S)-2-((S)-2-((S)-2-((S)-2-((S)-1-(D-alanyl-L-seryl)pyrrolidine-2-carboxamido)-4-(methylthio)butanamido)-4-methylpentanamido)-3-methylbutanamido)propanamido)-3-(4-hydroxy |
| Molecular Formula | C46H72N10O15S |
| Purity | ≥95% |
| Target | Immunology/Inflammation |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(1R)-1-carboxyethyl]amino]-4-oxobutanoic acid |
| InChI | InChI=1S/C46H72N10O15S/c1-22(2)18-30(52-39(63)29(15-17-72-8)50-43(67)34-10-9-16-56(34)45(69)33(21-57)54-37(61)24(5)47)42(66)55-36(23(3)4)44(68)48-25(6)38(62)51-31(19-27-11-13-28(58)14-12-27)41(65)53-32(20-35(59)60)40(64)49-26(7)46(70)71/h11-14,22-26,29-34,36,57-58H,9-10,15-21,47H2,1-8H3,(H,48,68)(H,49,64)(H,50,67)(H,51,62)(H,52,63)(H,53,65)(H,54,61)(H,55,66)(H,59,60)(H,70,71)/t24-,25+,26-,29+,30+,31+,32+,33+,34+,36+/m1/s1 |
| InChIKey | VRNHFZYMPDKTBS-WYUJEMNCSA-N |
| SMILES | C[C@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)O)N |
| Reference | </br> 1:Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY Sr, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J Med Chem. 2015 Jan 8;58(1):294-304. doi: 10.1021/jm501147g. Epub 2014 Nov 5. PubMed PMID: 25347203.</br> 2:LIDDLE HV, THOMAS JM. AB-103 (NSC-37096) IN THE TREATMENT OF BRONCHOGENIC CARCINOMA. Cancer Chemother Rep. 1964 Jul;39:61-5. PubMed PMID: 14201277.</br> 3: MECHL Z, KOLAR V, KONECNY M. THE USE OF THE DRUGS AB 103 AND AB 132 IN THE COMBINED TREATMENT OF TUMOURS OF THE CERVICAL AND PULMONARY REGIONS. Neoplasma. 1964;11:491-8. PubMed PMID: 14220338. |
